About Transcription factor YY2
Transcription factor YY2 (YY2) is a protein
from Homo sapiens identified by UniProt accession
O15391, 372 residues long.
MolForge cross-references it against 0 known binders and
26 disease associations.
Target properties
| Protein name | Transcription factor YY2 |
|---|
| UniProt accession | O15391 |
|---|
| Gene | YY2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 372 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (26)
Diseases linked to this target (Open Targets).
- osteogenesis imperfecta · score 0.12
- keratosis follicularis spinulosa decalvans · score 0.12
- IFAP syndrome 1, with or without BRESHECK syndrome · score 0.12
- Olmsted syndrome 1 · score 0.12
- neoplasm · score 0.11
- hepatocellular carcinoma · score 0.07
- cardiomyopathy · score 0.06
- cervical squamous intraepithelial neoplasia · score 0.06
- Osteoporosis · score 0.04
- Microphthalmia - ankyloblepharon - intellectual disability · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O15391-F1 | alphafold | PREDICTED | 56.54 | — |
Amino-acid sequence (372 residues)
MASNEDFSIT QDLEIPADIV ELHDINVEPL PMEDIPTESV QYEDVDGNWI YGGHNHPPLM VLQPLFTNTG YGDHDQEMLM LQTQEEVVGY CDSDNQLGND LEDQLALPDS IEDEHFQMTL ASLSASAAST STSTQSRSKK PSKKPSGKSA TSTEANPAGS SSSLGTRKWE QKQMQVKTLE GEFSVTMWSP NDNNDQGAVG EGQAENPPDY SEYLKGKKLP PGGLPGIDLS DPKQLAEFTK VKPKRSKGEP PKTVPCSYSG CEKMFRDYAA MRKHLHIHGP RVHVCAECGK AFLESSKLRR HQLVHTGEKP FQCTFEGCGK RFSLDFNLRT HLRIHTGDKP FVCPFDVCNR KFAQSTNLKT HILTHVKTKN NP
Explore Transcription factor YY2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets